@article{2ed67297172d448c8dd9eb8f3b7f18b9,
title = "Enabling the Sharing of Single-Dose Vials Through Risk Mitigation to Decrease Financial Toxicity",
author = "Goldstein, {Daniel A.} and Harvey, {R. Donald} and Chan, {Kelvin K.W.}",
note = "Funding Information: reported receiving personal fees from Vivio Health and institutional research funding from BMS Institutional Research Funding, MSD Institutional Research Funding, and Janssen Institutional Research Funding outside the submitted work. Dr Harvey reported receiving institutional research funding from Abbisko, AbbVie, Actuate, Alkermes, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boston Biomedical, Calithera, FujiFilm, Genmab, GlaxoSmithKline, Infinity, InhibRx, Janssen, Lycera, Merck, Mersana, Meryx, Nektar, Pfizer, Puma, RAPT Therapeutics, Regeneron, Rgenix, Sanofi, Seattle Genetics, Sutro, Takeda, Xencor; and consulting fees from Amgen and GlaxoSmithKline. Dr Chan has no interests to declare. No other disclosures were reported.",
year = "2022",
month = jun,
doi = "10.1001/jamaoncol.2022.0177",
language = "אנגלית",
volume = "8",
pages = "821--822",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "6",
}
